| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Department of Pathology and Microbiology, School of Medical Sciences, University of Bristol, Bristol, United Kingdom; and
Peptide Therapeutics Ltd., Cambridge, United Kingdom
The use of altered peptide ligands (APL) to modulate T cell responses has been suggested as a means of treating T cell-mediated autoimmune disorders. We have assessed the therapeutic potential of TCR antagonist peptides in autoimmunity using murine experimental autoimmune encephalomyelitis (EAE) as a model. The Tg4 transgenic mouse expresses an MHC class II-restricted TCR specific for the immunodominant encephalitogenic epitope of myelin basic protein, Ac1–9 (acetylated N-terminal nonamer). We have used T cell lines derived from Tg4 mice to define the TCR contact residues within Ac1–9. APL with appropriate substitutions at the primary TCR contact residue were effective antagonists of Tg4 T cells. These antagonist APL, however, were found to induce EAE in susceptible, nontransgenic strains of mice. Underlying this, the Ac1–9-specific T cell repertoire of normal mice, rather than reflecting the Tg4 phenotype, showed considerable diversity in fine specificity and was able to respond to the Tg4 antagonist APL. Defining antagonist APL in vitro using T cell clones, therefore, was not a reliable approach for the identification of APL with EAE-suppressing potential in vivo. Our findings highlight the complexities of the autoreactive T cell repertoire and have major implications for the use of APL in autoimmune diseases.
This article has been cited by other articles:
|
|
 |
|
  W. Mi, S. Wanjie, S.-T. Lo, Z. Gan, B. Pickl-Herk, R. J. Ober, and E. S. Ward Targeting the Neonatal Fc Receptor for Antigen Delivery Using Engineered Fc Fragments J. Immunol., December 1, 2008; 181(11): 7550 - 7561. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. A. Wasserman, C. D. Beal, Y. Zhang, N. Jiang, C. Zhu, and B. D. Evavold MHC Variant Peptide-Mediated Anergy of Encephalitogenic T Cells Requires SHP-1 J. Immunol., November 15, 2008; 181(10): 6843 - 6849. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Stephens, D. Gray, and S. M. Anderton CD4+CD25+ regulatory T cells limit the risk of autoimmune disease arising from T cell receptor crossreactivity PNAS, November 29, 2005; 102(48): 17418 - 17423. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Scotta, L. Tuosto, A. M. Masci, L. Racioppi, E. Piccolella, and L. Frasca Hypervariable region 1 variant acting as TCR antagonist affects hepatitis C virus-specific CD4+ T cell repertoire by favoring CD95-mediated apoptosis J. Leukoc. Biol., August 1, 2005; 78(2): 372 - 382. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. D. Margot, M. L. Ford, and B. D. Evavold Amelioration of Established Experimental Autoimmune Encephalomyelitis by an MHC Anchor-Substituted Variant of Proteolipid Protein 139-151 J. Immunol., March 15, 2005; 174(6): 3352 - 3358. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Ford and B. D. Evavold Regulation of Polyclonal T Cell Responses by an MHC Anchor-Substituted Variant of Myelin Oligodendrocyte Glycoprotein 35-55 J. Immunol., August 1, 2003; 171(3): 1247 - 1254. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. C. Garcia, C. G. Radu, J. Ho, R. J. Ober, and E. S. Ward Kinetics and thermodynamics of T cell receptor- autoantigen interactions in murine experimental autoimmune encephalomyelitis PNAS, June 5, 2001; 98(12): 6818 - 6823. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Anderton, C. G. Radu, P. A. Lowrey, E. S. Ward, and D. C. Wraith Negative Selection during the Peripheral Immune Response to Antigen J. Exp. Med., January 1, 2001; 193(1): 1 - 12. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. G. Radu, S. M. Anderton, M. Firan, D. C. Wraith, and E. S. Ward Detection of autoreactive T cells in H-2u mice using peptide-MHC multimers Int. Immunol., November 1, 2000; 12(11): 1553 - 1560. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
